메뉴 건너뛰기
New England Journal of Medicine
Volumn 360, Issue 20, 2009, Pages 2134-2136
Chemotherapy and immunotherapy in metastatic colorectal cancer [1]
Author keywords

[No Author keywords available]
Indexed keywords

ALBUMIN; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; HEMOGLOBIN; IMMUNOGLOBULIN; OXALIPLATIN; PLASMA PROTEIN; SERUM ALBUMIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;
EID: 65649105775     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc090489     Document Type: Letter
Times cited : (2)
References (5)
  • 1
    • 59749091477 scopus 로고    scopus 로고
    • Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer
    • Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360:563-572
    • (2009) N Engl J Med , vol.360 , pp. 563-572
    • Tol, J.1    Koopman, M.2    Cats, A.3
  • 2
    • 46049113331 scopus 로고    scopus 로고
    • An updated analysis of safety and efficacy of oxaliplatin (Ox)/bevacizumab (bev) +/- Panitumumab (pmab) for first-line treatment (tx) of metastatic colorectal cancer (mCRC) from a randomized, controlled trial (PACCE)
    • Presented at the abstract
    • Hecht JR, Mitchell E, Chidiac T, et al. An updated analysis of safety and efficacy of oxaliplatin (Ox)/bevacizumab (bev) +/- panitumumab (pmab) for first-line treatment (tx) of metastatic colorectal cancer (mCRC) from a randomized, controlled trial (PACCE). Presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Orlando, FL, January 25-27, 2008. abstract.
    • American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Orlando, FL, January 25-27, 2008
    • Hecht, J.R.1    Mitchell, E.2    Chidiac, T.3
  • 3
    • 0033790788 scopus 로고    scopus 로고
    • Early biotransformations of oxaliplatin after its intravenous administration to cancer patients
    • Allain P, Heudi O, Cailleux A, et al. Early biotransformations of oxaliplatin after its intravenous administration to cancer patients. Drug Metab Dispos 2000;28:1379-1384
    • (2000) Drug Metab Dispos , vol.28 , pp. 1379-1384
    • Allain, P.1    Heudi, O.2    Cailleux, A.3
  • 4
    • 0027146423 scopus 로고
    • In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin
    • Pendyala L, Creaven PJ. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res 1993;53:5970-5976
    • (1993) Cancer Res , vol.53 , pp. 5970-5976
    • Pendyala, L.1    Creaven, P.J.2
  • 5
    • 58849112551 scopus 로고    scopus 로고
    • Spectroscopic investigation on the binding of antineoplastic drug oxaliplatin to human serum albumin and molecular modeling
    • Yue Y, Chen X, Qin J, Yao X. Spectroscopic investigation on the binding of antineoplastic drug oxaliplatin to human serum albumin and molecular modeling. Colloids Surf B Biointerfaces 2009;69:51-57
    • (2009) Colloids Surf B Biointerfaces , vol.69 , pp. 51-57
    • Yue, Y.1    Chen, X.2    Qin, J.3    Yao, X.4

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.